Page 132 - 《中国药房》2024年9期
P. 132

[ 5 ]  JUSTO  J  A,BOSSO  J  A.  Adverse  reactions  associated   nal function[J]. Clin Microbiol Infect,2020:S1198-S743X
               with  systemic  polymyxin  therapy[J].  Pharmacotherapy,  (20)30727-8.
               2015,35(1):28-33.                              [16]  NORRBY S R. Neurotoxicity of carbapenem antibiotics:
          [ 6 ]  KARAISKOS I,GALANI I,PAPOUTSAKI V,et al. Car‐     consequences for their use in bacterial meningitis[J]. J An‐
               bapenemase  producing  Klebsiella  pneumoniae:implica‐  timicrob Chemother,2000,45(1):5-7.
               tion on future therapeutic strategies[J]. Expert Rev Anti In‐  [17]  MARTÍNEZ-RODRÍGUEZ  J  E, BARRIGA  F  J,
               fect Ther,2022,20(1):53-69.                         SANTAMARIA J,et al. Nonconvulsive status epilepticus
          [ 7 ]  AGBABIAKA T B,SAVOVIĆ J,ERNST E. Methods for      associated with cephalosporins in patients with renal fai-
               causality  assessment  of  adverse  drug  reactions:a  syste-   lure[J]. Am J Med,2001,111(2):115-119.
               matic review[J]. Drug Saf,2008,31(1):21-37.    [18]  DENIC A,GLASSOCK R J,RULE A D. Structural and
          [ 8 ]  刘双信,史伟,何思敏,等. 头孢他啶致慢性肾衰竭维持                        functional changes with the aging kidney[J]. Adv Chronic
               性透析患者中枢神经系统损害[J]. 中国血液净化,2010,                      Kidney Dis,2016,23(1):19-28.
               9(4):186-189.                                  [19]  LACROIX  C,KHELOUFI  F,MONTASTRUC  F,et  al.
               LIU S X,SHI W,HE S M,et al. Neurotoxicity induced by   Serious central nervous system side effects of cephalospo‐
               ceftazidime treatment in chronic renal failure patients on   rins:a national analysis of serious reports registered in the
               maintenance hemodialysis[J]. Chin J Blood Purif,2010,9  French  pharmacovigilance  database[J].  J  Neurol  Sci,
              (4):186-189.                                         2019,398:196-201.
          [ 9 ]  JOSEPH J,VIMALA A. Ceftazidime-induced myoclonus   [20]  COLLINS R D,TVERDEK F P,BRUNO J J,et al. Pro-
               and  encephalopathy  in  hemodialysis  patient[J].  Indian  J   bable  nonconvulsive  status  epilepticus  with  the  use  of
               Nephrol,2015,25(1):61-62.                           high-dose  continuous  infusion  ceftazidime[J].  J  Pharm
          [10]  DESHAYES S,COQUEREL A,VERDON R. Neurologi‐         Pract,2016,29(6):564-568.
               cal  adverse  effects  attributable  to  β -lactam  antibiotics:a   [21]  HURKACZ M,DOBREK L,WIELA-HOJEŃSKA A. An‐
               literature review[J]. Drug Saf,2017,40(12):1171-1198.  tibiotics and the nervous system:which face of antibiotic
          [11]  ONG  C  Y,QIN  Y.  Myoclonus  from  antibiotic  therapy   therapy  is  real,Dr.  Jekyll (neurotoxicity)  or  Mr.  Hyde
              (ceftazidime-induced neurotoxicity):a case report and re‐  (neuroprotection)?[J]. Molecules,2021,26(24):7456.
               view[J]. Cureus,2018,10(3):e2250.              [22]  REZAEI N J,BAZZAZI A M,NASERI ALAVI S A. Neu‐
          [12]  GATTI  M,RASCHI  E,PONTI  F  D.  Serious  adverse   rotoxicity  of  the  antibiotics:a  comprehensive  study[J].
               events  with  novel  beta-lactam/beta-lactamase  inhibitor   Neurol India,2018,66(6):1732-1740.
               combinations:a  large-scale  pharmacovigilance  analysis  [23]  BANGERT M K,HASBUN R. Neurological and psychia-
               [J]. Eur J Clin Microbiol Infect Dis,2021,40(6):1169-  tric  adverse  effects  of  antimicrobials[J].  CNS  Drugs,
               1176.                                               2019,33(8):727-753.
          [13]  GUO X L,GUO M X,LI J Y,et al. Central nervous sys‐  [24]  KERLING D A,CLARKE S C,DELUCA J P,et al. Sys‐
               tem adverse events of ceftazidime/avibactam:a retrospec‐  tematic  review  and  meta-analysis  of  the  effect  of  loop
               tive  study  using  Food  and  Drug  Administration  adverse   diuretics on antibiotic pharmacokinetics[J]. Pharmaceutics,
               event  reporting  system[J].  J  Clin  Pharm  Ther,2022,47  2023,15(5):1411.
              (12):2369-2372.                                 [25]  ABDUL-AZIZ M H,ALFFENAAR J C,BASSETTI M,
          [14]  郭晓龙,见海超,张志琪,等. 基于FAERS的头孢他啶/阿                      et  al. Antimicrobial  therapeutic  drug  monitoring  in  criti‐
               维巴坦致神经系统异常的不良反应信号挖掘与分析[J].                          cally ill adult patients:a position paper[J]. Intensive Care
               中国医院药学杂志,2022,42(19):2046-2050.                     Med,2020,46(6):1127-1153.
               GUO X L,JIAN H C,ZHANG Z Q,et al. Signal mining   [26]  BEUMIER  M,CASU  G  S,HITES  M,et  al.  Elevated
               and analysis of adverse drug reactions associated with ner‐  β-lactam concentrations associated with neurological dete‐
               vous  system  disorders  induced  by  ceftazidime/avibactam   rioration  in  ICU  septic  patients[J].  Minerva  Anestesiol,
               based on FAERS database[J]. Chin J Hosp Pharm,2022,  2015,81(5):497-506.
               42(19):2046-2050.                                            (收稿日期:2023-10-24  修回日期:2024-03-23)
          [15]  PINGUE V,PENATI R,NARDONE A,et al. Ceftazidime/                                   (编辑:刘明伟)
               avibactam neurotoxicity in an adult patient with normal re‐





          · 1150 ·    China Pharmacy  2024 Vol. 35  No. 9                              中国药房  2024年第35卷第9期
   127   128   129   130   131   132   133   134   135   136   137